Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

FINAL PX: Oriflame $550m 5NC2 fixed at 5.125%; E250m 5NC1 FRN at E+425bp

HYC US Market: Deal Flow - GeneralHYC European Market: Deal Flow - General

Oriflame Investment Holding Plc EUR709m equivalent (US$/EUR) 144A/Reg S sr sec notes 2-part. B1/B+/BB- (stable/stable/stable). Via GS/SEB jt glocos and physical books/HSBC jt books, ING as co-manager. List ISE, NY law. No reg rights.

- USD550m expected size fixed-rate notes due 2026 (5y). NC2 (MWC T+50bp) (50%,25%,par). Equity claw: 2y: 40%. IPT: mid 5% area. Final px: 5.125%.

- EUR250m expected size FRN due 2026 (5y). NC1 (MWC B+50bp) (101,par). IPT: E+450-475bp. Final px: 3moE+425bp.

Roadshow 04/19-21 (investor call at 2pm UKT 04/19). Pricing today. UOP: along with EUR96m cash on hand, to redeem EUR797m existing notes (EUR475m euro notes, plus EUR24m MWC premium and US$335m dollar notes , plus USD22.1m MWC premium). Biz: international direct selling of beauty products. HQ: Schaffhausen, Switzerland.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.